We aimed to elucidate the diagnostic potential of the C-X-C motif chemokine receptor 4 (CXCR4)-directed positron emission tomography (PET) tracer Ga-Pentixafor in patients with poorly differentiated neuroendocrine carcinomas (NEC), relative to the established reference standard F-FDG PET/computed tomography (CT). In our database, we retrospectively identified 11 treatment-naïve patients with histologically proven NEC, who underwent F-FDG and CXCR4-directed PET/CT for staging and therapy planning. The images were analyzed on a per-patient and per-lesion basis and compared to immunohistochemical staining (IHC) of CXCR4 from PET-guided biopsies. Ga-Pentixafor visualized tumor lesions in 10/11 subjects, whileF-FDG revealed sites of disease in all 11 patients. Although weak to moderate CXCR4 expression could be corroborated by IHC in 10/11 cases, F-FDG PET/CT detected significantly more tumor lesions (102 vs. 42; total lesions, = 107; < 0.001). Semi-quantitative analysis revealed markedly higher F-FDG uptake as compared to Ga-Pentixafor (maximum and mean standardized uptake values (SUV) and tumor-to-background ratios (TBR) of cancerous lesions, SUV: 12.8 ± 9.8 vs. 5.2 ± 3.7; SUV: 7.4 ± 5.4 vs. 3.1 ± 3.2, < 0.001; and, TBR 7.2 ± 7.9 vs. 3.4 ± 3.0, < 0.001). Non-invasive imaging of CXCR4 expression in NEC is inferior to the reference standard F-FDG PET/CT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067200 | PMC |
| http://dx.doi.org/10.3390/diagnostics11040605 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Tc]-PentixaTec SPECT/CT for Imaging of Chemokine Receptor 4 Expression After Myocardial Infarction.
Circ Cardiovasc Imaging
November 2024
Nuclear Medicine, Faculty of Medicine (A.L., R.A.B., C.H.P., M.K., G.W., C.L.), University of Augsburg, Germany.
Article Synopsis
- The study explores the use of a novel SPECT tracer, [Tc]-PentixaTec, to visualize CXCR4-positive immune cells in patients after an acute myocardial infarction (AMI).
- In a retrospective analysis of 9 AMI patients, increased CXCR4 expression was found in areas with reduced blood flow, indicating localized inflammation in the heart.
- The findings suggest that CXCR4 imaging could serve as a potential tool for assessing inflammation post-AMI, even though there was no significant correlation with common blood markers of heart damage.
C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy Using [Tc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study.
J Nucl Med
October 2024
Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
C-X-C motif chemokine receptor 4 (CXCR4)-directed imaging has gained clinical interest in aiding clinical diagnostics in primary aldosteronism (PA). We retrospectively evaluated the feasibility of CXCR4-directed scintigraphy using the novel CXCR-4 ligand [Tc]Tc-pentixatec in patients with PA. Six patients (mean age ± SD, 49 ± 15 y) underwent CXCR4-directed scintigraphy (including planar imaging and SPECT/CT) 30, 120, and 240 min after injection of 435 ± 50 MBq of [Tc]Tc-pentixatec.
View Article and Find Full Text PDFInterobserver Agreement Rates on CXCR4-Directed PET/CT in Patients with Marginal Zone Lymphoma.
Mol Imaging Biol
October 2024
Nuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany.
Unlabelled: C-X-C motif chemokine receptor 4 (CXCR4)-directed molecular imaging provides excellent read-out capabilities in patients with marginal zone lymphoma (MZL). We aimed to determine the interobserver agreement rate of CXCR4-targeted PET/CT among readers with different levels of experience.
Methods: 50 subjects with MZL underwent CXCR4-targeted PET/CT, which were reviewed by four readers (including two experienced and two less experienced observers).
Chemokine Receptor-4 Targeted PET/CT Imaging with Ga-Pentixafor in Head and Neck Cancer-A Comparison with F-FDG and CXCR4 Immunohistochemistry.
Diagnostics (Basel)
June 2024
Department of Nuclear Medicine, College of Health Sciences, University of KwaZulu Natal, Private Bag X54001, Durban 4001, South Africa.
Background: Head and neck squamous cell carcinoma (HNSCC) is common, and its incidence is increasing, particularly in HIV-infected individuals who present with more aggressive disease. Despite aggressive treatment, the prognosis remains poor because of resistance to chemoradiation therapy. So far, studies report very low [Ga]Ga-Pentixafor avidity in HNSCC.
View Article and Find Full Text PDFComparison of [F]FDG and [ Ga]pentixafor PET/CT in Nasopharyngeal Carcinoma.
Mol Imaging Biol
August 2024
Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
Article Synopsis
- The study investigated the use of [Ga]pentixafor PET/CT for detecting nasopharyngeal carcinoma (NPC) and compared its effectiveness to the traditional [F]FDG PET/CT.
- A total of 25 NPC patients participated, showing equivalent detection rates for primary tumors (96% for both tracers) but differences in uptake values, with [Ga]pentixafor generally being lower.
- The findings suggest that [Ga]pentixafor PET/CT is a viable alternative for identifying NPC, particularly for primary and metastatic lesions, and could be useful in patient treatment planning.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!